Physician profile
Jay J Schmidt
NPI 1083654271
$253.68
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $38.55 · 2021: $53.70 · 2022: $12.93.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $64.84 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $47.44 | 2019 | |
| Sunovion Pharmaceuticals INC. | $40.43 | 2019 | |
| Astellas Pharma US INC | $28.89 | 2021 | |
| Abbvie INC. | $24.65 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $21.84 | 2019 | |
| Dexcom, INC. | $13.09 | 2021 | |
| Lilly USA, LLC | $12.50 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.